Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:JAZZ NASDAQ:MRTX NASDAQ:MRVI NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$7.27+0.3%$6.87$4.25▼$9.85$2.69B0.482.06 million shs3.07 million shsJAZZJazz Pharmaceuticals$126.16-1.8%$118.59$95.49▼$148.06$7.65B0.24685,484 shs559,937 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/AMRVIMaravai LifeSciences$2.67-4.3%$2.49$1.66▼$9.50$681.81M0.29918,439 shs1.20 million shsUTHRUnited Therapeutics$405.02+0.0%$318.53$266.98▼$436.95$18.27B0.62867,639 shs626,423 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos0.00%-1.02%-12.83%+23.12%+15.03%JAZZJazz Pharmaceuticals0.00%-2.58%+7.12%+15.07%+15.97%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%MRVIMaravai LifeSciences0.00%+6.37%+2.30%+23.61%-68.18%UTHRUnited Therapeutics0.00%+1.12%+29.35%+40.36%+19.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$7.27+0.3%$6.87$4.25▼$9.85$2.69B0.482.06 million shs3.07 million shsJAZZJazz Pharmaceuticals$126.16-1.8%$118.59$95.49▼$148.06$7.65B0.24685,484 shs559,937 shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/AMRVIMaravai LifeSciences$2.67-4.3%$2.49$1.66▼$9.50$681.81M0.29918,439 shs1.20 million shsUTHRUnited Therapeutics$405.02+0.0%$318.53$266.98▼$436.95$18.27B0.62867,639 shs626,423 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos0.00%-1.02%-12.83%+23.12%+15.03%JAZZJazz Pharmaceuticals0.00%-2.58%+7.12%+15.07%+15.97%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%MRVIMaravai LifeSciences0.00%+6.37%+2.30%+23.61%-68.18%UTHRUnited Therapeutics0.00%+1.12%+29.35%+40.36%+19.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 2.00Hold$9.0023.80% UpsideJAZZJazz Pharmaceuticals 2.88Moderate Buy$178.6741.62% UpsideMRTXMirati Therapeutics 0.00N/AN/AN/AMRVIMaravai LifeSciences 2.18Hold$5.2295.46% UpsideUTHRUnited Therapeutics 2.69Moderate Buy$438.858.35% UpsideCurrent Analyst Ratings BreakdownLatest UTHR, JAZZ, MRVI, BHC, and MRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025UTHRUnited TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$405.00 ➝ $525.009/5/2025UTHRUnited TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$510.00 ➝ $575.009/5/2025UTHRUnited TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$400.00 ➝ $500.009/4/2025UTHRUnited TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$415.00 ➝ $560.009/3/2025UTHRUnited TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$295.00 ➝ $414.009/2/2025UTHRUnited TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$432.00 ➝ $564.009/2/2025UTHRUnited TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$314.00 ➝ $463.008/29/2025JAZZJazz PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$162.00 ➝ $185.008/28/2025JAZZJazz PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$162.00 ➝ $163.008/28/2025JAZZJazz PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$145.00 ➝ $151.008/28/2025JAZZJazz PharmaceuticalsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$200.00 ➝ $205.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.63B0.28$7.73 per share0.94($0.89) per share-8.17JAZZJazz Pharmaceuticals$4.09B1.87$30.33 per share4.16$67.72 per share1.86MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39MRVIMaravai LifeSciences$259.18M2.63$0.62 per share4.32$2.28 per share1.17UTHRUnited Therapeutics$2.88B6.35$28.38 per share14.27$144.34 per share2.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M$0.2627.961.56N/A0.99%-852.36%5.25%10/29/2025 (Estimated)JAZZJazz Pharmaceuticals$560.12M-$6.73N/A6.747.82-9.91%5.02%1.73%11/5/2025 (Estimated)MRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/AMRVIMaravai LifeSciences-$144.85M-$1.36N/AN/AN/A-90.03%-17.60%-9.30%11/6/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.6215.8114.736.1740.36%18.73%16.49%10/29/2025 (Estimated)Latest UTHR, JAZZ, MRVI, BHC, and MRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025JAZZJazz Pharmaceuticals-$5.61-$8.25-$2.64-$11.74$1.05 billion$1.05 billion7/30/2025Q2 2025BHCBausch Health Cos$0.97$0.90-$0.07$0.40$2.47 billion$2.57 billion7/30/2025Q2 2025UTHRUnited Therapeutics$6.80$6.41-$0.39$6.41$802.13 million$798.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/AMRTXMirati TherapeuticsN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos141.901.310.98JAZZJazz Pharmaceuticals1.171.621.37MRTXMirati TherapeuticsN/A7.547.40MRVIMaravai LifeSciences0.685.164.49UTHRUnited TherapeuticsN/A7.266.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%JAZZJazz Pharmaceuticals89.14%MRTXMirati TherapeuticsN/AMRVIMaravai LifeSciences50.25%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos19.97%JAZZJazz Pharmaceuticals4.30%MRTXMirati Therapeutics3.26%MRVIMaravai LifeSciences2.11%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.35 million296.39 millionOptionableJAZZJazz Pharmaceuticals2,80060.66 million58.05 millionOptionableMRTXMirati Therapeutics58770.15 million67.86 millionOptionableMRVIMaravai LifeSciences610255.36 million249.97 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableUTHR, JAZZ, MRVI, BHC, and MRTX HeadlinesRecent News About These CompaniesFY2025 EPS Estimates for UTHR Raised by Cantor FitzgeraldSeptember 14 at 6:34 AM | marketbeat.comInspire Investing LLC Sells 1,237 Shares of United Therapeutics Corporation $UTHRSeptember 14 at 5:56 AM | marketbeat.comUTHR FY2025 EPS Forecast Lifted by Cantor FitzgeraldSeptember 14 at 2:29 AM | americanbankingnews.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $1,588,920.00 in StockSeptember 13 at 8:34 PM | marketbeat.comFY2026 EPS Estimates for UTHR Increased by Cantor FitzgeraldSeptember 13 at 7:54 AM | marketbeat.comAcadian Asset Management LLC Acquires 169,010 Shares of United Therapeutics Corporation $UTHRSeptember 13 at 5:35 AM | marketbeat.comFred Alger Management LLC Makes New $256,000 Investment in United Therapeutics Corporation $UTHRSeptember 13 at 4:08 AM | marketbeat.comEquities Analysts Offer Predictions for UTHR FY2026 EarningsSeptember 13 at 2:43 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Director Sells $280,203.00 in StockSeptember 12 at 5:36 PM | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 4,560 Shares of StockSeptember 12 at 5:36 PM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) COO Sells $1,961,050.00 in StockSeptember 12 at 5:36 PM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,000 SharesSeptember 12 at 5:36 PM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) COO Sells $4,520,538.75 in StockSeptember 12 at 5:36 PM | marketbeat.comCantor Fitzgerald Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock PriceSeptember 12 at 9:37 AM | marketbeat.com21,112 Shares in United Therapeutics Corporation $UTHR Acquired by Capital Impact Advisors LLCSeptember 12 at 8:17 AM | marketbeat.comMartine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) StockSeptember 12 at 7:25 AM | insidertrades.comUnited Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society CongressSeptember 12 at 7:00 AM | businesswire.comAshton Thomas Private Wealth LLC Has $1.44 Million Stock Position in United Therapeutics Corporation $UTHRSeptember 12 at 5:12 AM | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Bought by Jacobs Levy Equity Management Inc.September 12 at 3:55 AM | marketbeat.comUnited Therapeutics Price Strength Rating Jumps; Stock Soared 33% Last WeekSeptember 12 at 2:51 AM | investors.comCantor Fitzgerald Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) StockSeptember 12 at 2:10 AM | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUTHR, JAZZ, MRVI, BHC, and MRTX Company DescriptionsBausch Health Cos NYSE:BHC$7.27 +0.02 (+0.28%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$7.20 -0.07 (-1.03%) As of 09/12/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Jazz Pharmaceuticals NASDAQ:JAZZ$126.16 -2.30 (-1.79%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$126.18 +0.03 (+0.02%) As of 09/12/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Maravai LifeSciences NASDAQ:MRVI$2.67 -0.12 (-4.30%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.67 0.00 (0.00%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.United Therapeutics NASDAQ:UTHR$405.02 +0.18 (+0.04%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$399.94 -5.08 (-1.25%) As of 09/12/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
